On March 20, 2026, Tevogen Bio Holdings Inc. announced that it has received a Notification Letter from The Nasdaq Stock Market LLC confirming that the company has regained compliance with the minimum bid price requirement as outlined in Nasdaq Listing Rule 5450(a)(1). This notification comes after the company implemented a 1-for-50 reverse stock split of its common stock, effective March 6, 2026. The reverse stock split was a strategic move aimed at increasing the stock price to meet Nasdaq's listing standards. The company had previously faced challenges in maintaining its listing due to its stock price falling below the required minimum. With this compliance, Tevogen Bio Holdings can continue to trade on The Nasdaq Global Market, which is crucial for its visibility and access to capital markets. The company has indicated that further details regarding the reverse stock split can be found in its Current Report on Form 8-K filed on March 4, 2026. This development is expected to have a small positive effect on the stock price as it alleviates concerns regarding the company's listing status and enhances investor confidence.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.